The Promise of Artificial Intelligence to Aid in Systematic Reviews: An Examination of Scopus AI - Top-Institutions - MDSpire

The Promise of Artificial Intelligence to Aid in Systematic Reviews: An Examination of Scopus AI

AI tools such as Scopus AI can aid APP researchers and clinicians to streamline specific aspects such as the initial tasks and literature search steps of the systematic review development process.

  • By

  • Lydia T. Madsen

  • John C. Carter

  • Sheeba Cantanelli

  • Christine Hong

  • Angela F. Bazzell

  • March 4, 2026

  • 13 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, Maryland

    Key Differentiators

    • Evidence-Based Practice
    • Clinical Research

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Evidence-Based Practice
    • Clinical Research

  • #3

    Stanford University
    Stanford University

    Stanford, California

    Key Differentiators

    • Biomedical Data Science
    • Clinical Research

  • #4

    Columbia University
    Columbia University

    New York, New York

    Key Differentiators

    • Clinical Research
    • Public Health

  • #5

    University of Chicago
    University of Chicago

    Chicago, Illinois

    Key Differentiators

    • Clinical Research
    • Public Health

Original Source(s)

The Promise of Artificial Intelligence to Aid in Systematic Reviews: An Examination of Scopus AI

  • by Lydia T. Madsen, John C. Carter, Sheeba Cantanelli, Christine Hong, Angela F. Bazzell

  • March 4, 2026

Related Content

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min
Case Report: A rare case of over 45 years’ survival in a patient with tonsillar adenoid cystic carcinoma

Chemotherapy-related cognitive impairment and non-pharmacological interventions targeting the nervous system: a systematic review